Biocon licenses three generic formulation products to China Medical System Holdings
Under the terms of the agreement, Biocon will be responsible for the development, manufacturing and supply of the products…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biocon
USFDA issues response letter for new drug application for insulin glargine: Biocon
As per the USFDA, a Complete Response Letter (CRL) is sent to an applicant if the agency determines that it will not approve the…
Biocon’s Malaysia Insulin glargine facility receives Certificate of GMP
The approval expands Biocon’s capacities, with new large scale devices facility coming up to speed to serve growing needs of…
Mylan and Biocon launch first Trastuzumab Biosimilar, Ogivri, in Australia
Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme…
Biocon Q1FY20 Revenue grows by 25 per cent
EBITDA up 51 per cent at Rs 462 crores, net profit (excluding exceptional item) up 86 per cent at Rs 223 crores, small molecules…
Notices issued to companies for introducing drugs without prior nod from NPPA: Government
The drugs include those used for treating conditions like diabetes, inflammation and chronic hepatitis C, among others
Kiran Mazumdar-Shaw, husband make largest donation to Scottish University
The USD 5 million contribution would be contributed to the Research Hub, currently under construction on the Western Infirmary…
USFDA issues 12 observations for three Biocon units in Malaysia
The inspection across these three units concluded with 12 observations issued on the Form 483
Panel discussion: From formulation development to commercialisation of complex generics: Challenges…
FDD Conclave, a one-of-its-kind platform for formulation development and drug delivery professionals, is a thought leadership…
Biocon collaborates with JDRF
JDRF provides financial support to accelerate breakthrough research in Type 1 Diabetes management